Summit Therapeutics
SMMT
242 hedge funds and large institutions have $1.98B invested in Summit Therapeutics in 2026 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 96 increasing their positions, 57 reducing their positions, and 35 closing their positions.
68% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 57
66% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 35
14% more call options, than puts
Call options by funds: $59.1M | Put options by funds: $51.7M
9% more funds holding
Funds holding: 222 → 242 (+20)
2.17% more ownership
Funds ownership: 15.34% → 17.51% (+2.2%)
12% less capital invested
Capital invested by funds: $2.25B → $1.98B (-$273M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$74.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$51.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$44.5M |
| 4 |
Millennium Management
New York
|
+$39.4M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$35.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$77.7M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$63.9M |
| 3 |
D.E. Shaw & Co
New York
|
-$17.7M |
| 4 |
SCM
Superstring Capital Management
New York
|
-$16.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.4M |
SMMT Hedge Fund Activity: Q2 2026 in Review
242 of the 8,297 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q2 2026, worth a combined $1.98B — down 12% from $2.25B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new SMMT positions and 35 closed out — a net gain of 23 holders — while 96 added to existing stakes and 57 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $74.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $77.7M.
- 242 institutional investors held Summit Therapeutics (SMMT) as of Q2 2026, up from 222 in Q1 2026.
- Funds reported $1.98B of Summit Therapeutics stock for Q2 2026, down 12% quarter-over-quarter.
- 58 funds opened new Summit Therapeutics positions in Q2 2026 and 35 closed out, a net change of +23 holders.
- The largest Summit Therapeutics buyer in Q2 2026 was Goldman Sachs, an estimated $74.5M added.
- The largest Summit Therapeutics seller in Q2 2026 was T. Rowe Price Associates, an estimated $77.7M sold.
Based on aggregated 13F filings for Q2 2026.